Recent Finacing
Recent Raise
Acetylon Pharmaceuticals develops orally administered, isoform-selective small-molecule HDAC inhibitors, including lead HDAC6 candidate ACY-1215, for multiple myeloma and broader oncology, autoimmune, and neurodegenerative indications.
Focus Areas
Recent Investors
Valuation as of 07/29/2013
Total Raised
Funding rounds
Investor